Entries by Roger Tatoud
Enterprise workshop trial design R4P
This scientific and technical workshop aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, held in November 2018 in Seattle by the Fred Hutch and the NIAID. Participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learned for current HIV prevention designs.
HIV R4P 2020 Abstract submissions now open
The Global HIV Vaccine Enterprise encourages HIV vaccine researches to submit abstracts online from 3 February to 23 April through the HIVR4P website. Late breaker abstracts will be accepted from 23 July – 5 August. Abstracts about HIV vaccine research and development can be submitted across a range of categories from basic science to product implementation.
The search for a preventive HIV vaccine must go on
The Global HIV Vaccine Enterprise (the Enterprise), hosted by the International AIDS Society (IAS), shares the deep disappointment that the Phase 2b/3 HIV vaccine study HVTN 702 has been stopped by the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID). The decision to halt the trial, conducted by the HIV Vaccine Trials Network (HVTN), follows the recommendation of the independent Data and Safety Monitoring Board (DSMB). Although the regimen did not prevent HIV infections, the DSMB did not express any concerns about safety.
Meeting Report: Sustaining and strengthening HIV vaccine R&D in Europe
The Global HIV Vaccine Enterprise (the Enterprise) meeting in Ghent, Belgium, provided an opportunity to engage as a region on critical issues, including political and research commitments in Europe, with the aim of ensuring that HIV vaccine R&D remains a key priority in a challenging and changing global health landscape.
Viewpoint: The complex challenges of HIV vaccine development
In this viewpoint published in The Lancet, key stakeholders look into the challenges of developing an HIV vaccine from development to marketing.
ICASA 2019 Road Map of HIV Vaccine Research and Development
The Global HIV Vaccine Enterprise is looking forward to the 20th International Conference on AIDS and STIs in Africa (ICASA 2019) taking place on 2-7th December 2019 in Kigali, Rwanda.
ICASA represents the largest AIDS conference in Africa with over 10 000 delegates expected. The conference theme for 2019 is “AIDS free Africa – Innovation, Community and Political Leadership”. This is a tremendous opportunity for the international community to join efforts in committing to achieving an AIDS-free Africa.
Enterprise Workshop – Kigali 2019
Are you an African researcher or a clinician working on HIV vaccine research and development (R&D)? Are you interested in sharing your experience and the challenges you face in your daily work? Are you keen to develop practical solutions to support African researchers towards the development of a safe and effective HIV vaccine?
The Global HIV Vaccine Enterprise invites you to apply to attend an interactive half-day workshop in Kigali.
Strengthening African leadership in the new EU-Africa global health research partnerships
The Enterprise welcomes the European Union (EU) commitment to increase health security in sub-Saharan Africa and Europe, building on the current partnership between the EU, its Member States and sub-Saharan countries. These partnerships are essential for facilitating research, developing and improving health technologies, which in turn contributes to reducing the burden of infectious diseases.
IAS 2019: Promising HIV Vaccine Study Results Point to the Need to Intensify and Accelerate Preparation for Future Research and Access Challenges
The Global HIV Vaccine Enterprise welcomes the important and encouraging results of the ASCENT study and new clinical data from the APPROACH study presented at the 10th IAS Conference on HIV Science (IAS 2019), held in Mexico City, Mexico. These two studies build on the success of previous research using mosaic-based vaccines and provide important data to inform ongoing efforts to develop an effective, implementable vaccine regimen – a central part of a comprehensive, global HIV prevention strategy.
Contact Us
